Phase II Trial of Combined Modality Treatment in Primary Central Nervous System Lymphoma

You may be eligible if

• 1. Histological or cytological diagnosis of non-Hodgkin's lymphoma.
• 2. Diagnostic sample obtained by stereotactic or surgical biopsy, CSF cytology examination or vitrectomy.
• 3. Disease exclusively localized into the central nervous system, cranial nerves or eyes.
• 4. Untreated patients (patients treated with steroids alone are eligible).
• 5. At least one measurable lesion.
• 6. Age 18 - 75 years.
• 7. ECOG performance status \< 3
• 8. HBsAg-negative and Ab anti-HCV-negative serologic status.
• 9. No known HIV disease or immunodeficiency.
• 10. Adequate bone marrow (PLT \> 100000 mm3, Hb ≥ 9 g/dl, ANC ≥ 2.000 mm3), renal (creatinine clearance ≥ 60 mL/min), cardiac (VEF ≥ 50%), and hepatic function (total serum bilirubin \< 3 mg/dL, AST/ALT and gGT \< 2 per upper normal limit value).
• 11. No previous or concurrent malignancies with the exception of surgically cured cervical intraepithelial neoplasia type 1 (CIN1) or localized non-melanomatous skin cancer and of other cancers without evidence of disease since at least 5 years (patients with a previous lymphoma diagnosis will be excluded).
• 12. Absence of any familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
• 13. Non-pregnant and non-lactating status for female patients. Adequate contraceptive measures during study participation for sexually active patients of childbearing potential.
• 14. No concurrent treatment with other experimental drugs.
• 15. Informed consent signed by the patient before registration